Mode of enhancement in ribonucleic acid synthesis directed by chromium (III)-bound deoxyribonucleic acid.
By forming a complex with calf thymus DNA, Cr(III), i.e., CrCl3 and Cr(NO3)3, significantly enhanced its template activity for in vitro RNA synthesis as assayed by 3H incorporation from [5-3H]uridine triphosphate (UTP). The extent of the augmentation in RNA synthesis was proportional to the binding ratio of Cr(III) to the template DNA. K2CrO4, on the other hand, neither bound to DNA nor enhanced its template activity. Experiments using rifampicin and heparin suggested that incorrect and nonviable initiation sites for RNA synthesis became functional in Cr(III)-bound DNA. The incorporation of [gamma-32P]adenosine triphosphate (ATP) into RNA synthesized on Cr(III)-bound DNA was 8 to 9 times greater than that on control DNA. This value was much higher than that of the 3H incorporation form [5-3H]UTP, i.e., the incorporation of 32P on Cr(III) bound DNA was 8 to 9 times greater that of 3H and less than twice that on control DNA. These results suggest that Cr(III) possibly induces the abnormal synthesis of RNA of a very low molecular weight, for most if not all the molecules, by binding to the template DNA.
D000818:Animals; D002417:Cattle; D055598:Chemical Phenomena; D002621:Chemistry; D002857:Chromium / Q000494:pharmacology*; D004247:DNA; D012321:DNA-Directed RNA Polymerases / Q000378:metabolism; D004926:Escherichia coli / Q000201:enzymology; D006493:Heparin / Q000494:pharmacology; D007700:Kinetics; D012313:RNA / Q000235:genetics*; D012293:Rifampin / Q000494:pharmacology; D013698:Templates, Genetic; D013950:Thymus Gland / Q000378:metabolism; D014158:Transcription, Genetic / Q000187:drug effects*
D002857:Chromium; D012313:RNA; D006493:Heparin; D004247:DNA; D012321:DNA-Directed RNA Polymerases; D012293:Rifampin